Gilead Sciences Accrued rebates decreased by 5.0% to $4.12B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.6%, from $4.19B to $4.12B. Over 4 years (FY 2021 to FY 2025), Accrued rebates shows an upward trend with a 7.5% CAGR.
current_liabilities_accrued_rebates| Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.24B | $3.48B | $3.48B | $3.49B | $3.71B | $3.80B | $4.26B | $3.92B | $4.11B | $3.89B | $4.19B | $4.22B | $4.93B | $4.34B | $4.12B |
| QoQ Change | — | +7.2% | -0.1% | +0.5% | +6.3% | +2.4% | +12.1% | -8.0% | +4.8% | -5.4% | +7.5% | +0.7% | +17.0% | -12.0% | -5.0% |
| YoY Change | — | +7.2% | — | — | — | +9.3% | +22.6% | +12.3% | +10.7% | +2.4% | -1.8% | +7.4% | +19.9% | +11.4% | -1.6% |